Divestment12 Mar 2026, 04:29 pm
Sigma Advanced Systems Completes $15 Million Extrovis Divestment, Sharpening Aerospace and Defence Focus
AI Summary
Sigma Advanced Systems Ltd has completed the divestment of its entire 36.52% equity stake in Extrovis AG, a Switzerland-based pharmaceutical company, for $15 million. This move is part of Sigma's portfolio rationalisation strategy and its transformation into a pureplay aerospace and defence platform. The company aims to use the generated capital to strengthen manufacturing capabilities, pursue strategic acquisitions, and expand its presence across global defence and aerospace supply chains.
Key Highlights
- Sigma Advanced Systems has completed a $15 million divestment of its stake in Extrovis AG.
- This divestment is part of Sigma's portfolio rationalisation strategy and its transformation into a pureplay aerospace and defence platform.
- Sigma aims to use the generated capital to strengthen manufacturing capabilities, pursue strategic acquisitions, and expand its presence across global defence and aerospace supply chains.
- Sigma has been building a broader international platform, with recent acquisitions of AS Strategic and the Nasmyth Group.